Joseph Haas
Senior Writer
Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest From Joseph Haas
CalciMedica Eyes Success In Pancreatitis, Acute Kidney Injury
Phase IIb data for Auxora in an acute pancreatitis subpopulation is expected to set up the CRAC channel inhibitor for Phase III in that indication while suggesting positive read-through for AKI.
Savara’s Persistence May Pay Off In Rare Lung Disease
Five years after a Phase III failure, Savara reports pivotal data supporting approval of molgramostim as the first drug for autoimmune pulmonary alveolar proteinosis.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Sarepta Obtains Broader DMD Label For Elevidys
The gene therapy is now approved for all ambulatory boys with Duchenne muscular dystrophy ages 4 and older. The revised label also includes accelerated approval for non-ambulatory patients.
Gilead’s Twice-Annual Sunlenca Posts Zero Infection Rate In PrEP Trial
Lenacapavir is halfway to the pivotal data needed to file for twice-annual administration in PrEP, after demonstrating superiority against both background incidence of HIV infections and Truvada.
Intra-Cellular Poised To Add MDD To Caplyta’s Label
Caplyta succeeded in a second Phase III study as adjunctive therapy for major depression, putting the schizophrenia/bipolar disorder drug on track for sNDA filing later in 2024.